Drug intelligence / Profile preview

JMIT-DK06

Development stage: Unknown
Lead developer: Jianmin Pharmaceutical Group
Modality: Small Molecules
Administration: Ophthalmic

Overview

JMIT-DK06 is a clinical-stage drug candidate being developed by Jianmin Pharmaceutical Group for the treatment of dry eye disease. It is categorized as a non-pediatric therapeutic within the company's R&D pipeline, distinguishing it from their pediatric-focused 'JMEY' series. As of early 2024, JMIT-DK06 is in Phase 1 clinical trials. While the specific molecular target and mechanism of action have not been publicly disclosed, the candidate represents Jianmin's expansion into the ophthalmic therapeutic area.

Beyond the preview

Go deeper on JMIT-DK06.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JMIT-DK06.

Explore the full profile